Last reviewed · How we verify
celecoxib test formulation B2 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
celecoxib test formulation B2 (celecoxib test formulation B2) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| celecoxib test formulation B2 TARGET | celecoxib test formulation B2 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- celecoxib test formulation B2 CI watch — RSS
- celecoxib test formulation B2 CI watch — Atom
- celecoxib test formulation B2 CI watch — JSON
- celecoxib test formulation B2 alone — RSS
Cite this brief
Drug Landscape (2026). celecoxib test formulation B2 — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-test-formulation-b2. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab